EU/3/12/1086

About

On 24 January 2013, orphan designation (EU/3/12/1086) was granted by the European Commission to Cancer Prevention Pharma Limited, United Kingdom, for eflornithine in combination with sulindac for the treatment of familial adenomatous polyposis.

The sponsorship was transferred to Cancer Prevention Pharma (Ireland) Limited. Ireland, in April 2019.

Key facts

Active substance
Eflornithine
Disease / condition
Treatment of familial adenomatous polyposis (FAP)
Date of first decision
24/01/2013
Outcome
Positive
EU designation number
EU/3/12/1086

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Cancer Prevention Pharma (Ireland) Limited
70 Sir John Rogerson's Quay
Grand Canal Dock
Dublin 2
Ireland
Tel. +353 1 232 2000
E-mail: jjacob@canprevent.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating